Business Description
Mira Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US60458C1045
Compare
Compare
Traded in other countries / regions
MIRA.USAK6S.Germany IPO Date
2023-08-03Description
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2824 | |||||
| Equity-to-Asset | 0.74 | |||||
| Piotroski F-Score | N/A/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y EPS without NRI Growth Rate Estimate | 5.04 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48.62 | |||||
| 9-Day RSI | 38.36 | |||||
| 14-Day RSI | 39.54 | |||||
| 6-1 Month Momentum % | 79.82 | |||||
| 12-1 Month Momentum % | -57.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.68 | |||||
| Quick Ratio | 3.68 | |||||
| Cash Ratio | 3.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 5.18 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -335.33 | |||||
| ROA % | -259.84 | |||||
| ROIC % | -567.33 | |||||
| ROC (Joel Greenblatt) % | -12174.19 | |||||
| ROCE % | -253.68 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 7.73 | |||||
| Price-to-Tangible-Book | 7.73 | |||||
| EV-to-EBIT | -1.4 | |||||
| EV-to-EBITDA | -1.4 | |||||
| EV-to-FCF | -2.89 | |||||
| Price-to-Net-Current-Asset-Value | 8.29 | |||||
| Price-to-Net-Cash | 8.29 | |||||
| Earnings Yield (Greenblatt) % | -71.43 | |||||
| FCF Yield % | -27.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MIRA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Mira Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.882 | ||
| Beta | 0 | ||
| Volatility % | 274.43 | ||
| 14-Day RSI | 39.54 | ||
| 14-Day ATR ($) | 0.166356 | ||
| 20-Day SMA ($) | 1.3475 | ||
| 12-1 Month Momentum % | -57.85 | ||
| 52-Week Range ($) | 0.51 - 6.4 | ||
| Shares Outstanding (Mil) | 14.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Mira Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Mira Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Mira Pharmaceuticals Inc Frequently Asked Questions
What is Mira Pharmaceuticals Inc(MIRA)'s stock price today?
The current price of MIRA is $1.16. The 52 week high of MIRA is $6.40 and 52 week low is $0.51.
When is next earnings date of Mira Pharmaceuticals Inc(MIRA)?
The next earnings date of Mira Pharmaceuticals Inc(MIRA) is 2024-11-13 Est..
Does Mira Pharmaceuticals Inc(MIRA) pay dividends? If so, how much?
Mira Pharmaceuticals Inc(MIRA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers